← Back
$LYRA All transactions

Lyra Therapeutics, Inc.

A

$ Value

$0

Shares

3,667

Price

$0

Filed

Oct 3

Insider

Name

Palasis Maria

Title

President & CEO

CIK

0001810701

Roles

Director Officer

Transaction Details

Transaction Date

2025-10-01

Code

A

Table

Derivative

Ownership

Direct

Equity Swap

No

Shares After

7,333

Footnotes

On March 21, 2024, the Reporting Person was granted a performance stock option ("PSO") for an aggregate of up to 11,000 shares of common stock (or 550,000 shares on a pre-split basis) under the Issuer's 2020 Incentive Award Plan (the "Agreement"). Under the terms of the Agreement, the underlying PSO shares will vest upon certain milestone events. On October 1, 2025, the Issuer determined that Milestone 2 of the PSO was achieved, resulting in 3,667 PSOs being earned. The earned PSOs will vest on January 31, 2028.

Filing Info

Accession No.

0001193125-25-230193

Form Type

4

Issuer CIK

0001327273

Palasis Maria's History

Date Ticker Type Value
2026-04-01 LYRA D $0
2026-01-13 BBNX A $0
2026-01-06 LYRA $6K
2025-12-01 BBNX $27K
2025-12-01 BBNX $15K
2025-10-31 BBNX $35K
2025-10-31 BBNX $3K
2025-10-01 LYRA A $0
2025-07-10 LYRA $14K

Other Insiders at LYRA (90d)

Insider Bought Sold Last
Palasis Maria
Principal Executive Officer
2026-04-01
Cavalier Jason
Principal Financial Officer
2026-04-01